| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 09/22/2009 | US7592365 4-{4-[3-(2-fluoro-5-trifluoromethylphenyl)ureido]phenyl}-1H-pyrrole-3-carboxamide; anticarcinogenic agents; FAK, KDR and Tie2 kinase inhibitors |
| 09/22/2009 | US7592364 Substituted gamma lactams as therapeutic agents |
| 09/22/2009 | US7592363 Indazoles |
| 09/22/2009 | US7592362 Substituted imidazoles |
| 09/22/2009 | US7592361 Indole acetic acid derivatives and their use as pharmaceutical agents |
| 09/22/2009 | US7592360 3-fluoro-piperidines as NMDA/NR2B antagonists |
| 09/22/2009 | US7592359 Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists |
| 09/22/2009 | US7592358 Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds |
| 09/22/2009 | US7592357 Compounds |
| 09/22/2009 | US7592356 and geranylgeranyltransferase inhibitor; 3-chloromethyl-4-cyanobenzyl-5 methyl triazole; antitumor agents; prevent membrane attachment of protein p21ras and block aberrant growth of ras-transformed tumors; capable to inhibit prenylation of Ras proteins, both at enzymatic and cellular level |
| 09/22/2009 | US7592355 Quinolinone-carboxamide compounds as 5-HT, receptor agonists |
| 09/22/2009 | US7592354 Administering a stimulantfor the endogenous production/ release of somatotropins; 3-((1-(2-aminoprop-2-yl)carbonylamino-),2-(phenylmethoxymethyl-)ethyl-),5-(morpholino-carbonyloxymethyl-)-5,6,7,8-tetrahydro-1,2,4-triazolo(4,3-)pyridine; osteoporosis; obesity;improving bone densisty, muscle mass/strength |
| 09/22/2009 | US7592353 Substituted 3-amino-thieno[2,3-b]pyridine-2-carboxylic acid amide compounds and processes for preparing and their uses |
| 09/22/2009 | US7592352 e.g. 4-amino-3-(4-((2-fluoro-5-(trifluoromethyl)aminocarbonylamino)phenyl)-7-(3-chlorophenyl)-furo[3,2-c]pyridine; antiproliferative, anticarcinogenic, antitumor agent; solid tumor diseases, atherosclerosis, angiogenesis, vasculogenesis |
| 09/22/2009 | US7592351 5,7-Dimethyl-2-thiophen-3-yl-imidazo[1,2-a]pyridin-3-yl)-(1,1,3,3-tetramethylbutyl)-amine;vanilloid/cannabinoid receptor antagonists; analgesics, neuropathic pain; headaches; antiepileptic agents; emetic agents; eating disorders; hypotensive agents; antidepressants; glaucoma; incontinence; prion disease |
| 09/22/2009 | US7592350 Polycyclic compounds as potent alpha2-adrenoceptor antagonists |
| 09/22/2009 | US7592349 Diarylamine-containing compounds and compositions, and their use as modulators of c-kit receptors |
| 09/22/2009 | US7592348 Heterocyclic aspartyl protease inhibitors |
| 09/22/2009 | US7592347 Piperazine derivates and their use for the treatment of neurological and psychiatric diseases |
| 09/22/2009 | US7592346 e.g. 3-(3-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}phenyl)-1,3-oxazolidin-2-one; serotonin receptor antagonist and inverse agonists, agonists or partial agonists, serotonin reuptake inhibitor; antidepressant, anxiolytic agent |
| 09/22/2009 | US7592345 N-1-(4-chlorophenyl)-2-hydroxyethyl]-2-(3,4-dichloro-phenyl)-4-(1,1-dioxo-perhydroisothiazolo(2,3-a)pyrazin-5-yl)-2-methylbutyramide and -4-(4-alkylsulfonyl)piperazin-1-yl)-2-methylbutyramide; high potential neurokinin 3 (NK-3) receptor antagonists; antidepressants; analgesics; psychoses; hyperactivity |
| 09/22/2009 | US7592344 3-Cyano-N-(2-(3,4-dichlorophenyl)-4-{4-[(1R,2S)-1-(2-furyl)-2,3-dihydroxypropyl]piperazin-1-yl}butyl]-N-methyl-1-naphthamide; substance P receptor/neurokinin 2 receptor antagonists; antiinflammatory agents; emetic agents; asthma respiratory system disorders; antiarthritic agents; lupus; antiallergens |
| 09/22/2009 | US7592343 Pyridazine-piperazine compounds and their use as stearoyl-CoA desaturase inhibitors |
| 09/22/2009 | US7592342 Quinoxaline derivatives as PI3 kinase inhibitors |
| 09/22/2009 | US7592340 Quinoxalines useful as inhibitors of protein kinases |
| 09/22/2009 | US7592339 Substituted oxazolidinones and their use in the field of blood coagulation |
| 09/22/2009 | US7592338 (1-phenyl-5-propyl-1H-pyrazol-4-yl)-(3-amino-N-cyclopropyl-4-methyl-benzamide)-amine; p38 mitogen-activated protein kinase inhibitor; reduced levels of TNF- alpha expression; antiinfammatory agent: rheumatoid arthritis, psoriasis, multiple sclerosis, endotoxin shock, osteoporosis, Alzheimer's disease |
| 09/22/2009 | US7592337 Di-aryl substituted tetrazole modulators of metabotropic glutamate receptor-5 |
| 09/22/2009 | US7592336 Hepatitis C virus inhibitors |
| 09/22/2009 | US7592335 3-{3-fluoro-4-[(7aE)-hexahydropyrrolo[3,4-b][1,4]oxazin-4(4aH)-yl]phenyl}-5-(iodomethyl)-1,3-oxazolidin-2-one; antibiotics; preventing catheter infections; good activity against multiply resistant gram positive pathogens |
| 09/22/2009 | US7592334 6-[({3-hydroxy-8-[6-(methyloxy)-1,5-naphthyridin-4-yl]-8-azaspiro[4.5]dec-2-yl}amino)methyl]-2H-pyrido[3,2-b][1,4]thiazin-3-on; bacterial infections; antibiotic resistance; Staphylococcus aureus, Streptococcus pneumoniae and pyogenes, Enterococcus; Haemophilus influenzae, Moraxella catarrhalis, E-coli |
| 09/22/2009 | US7592333 Loxapine analogs and methods of use thereof |
| 09/22/2009 | US7592332 Cytokine inhibitors |
| 09/22/2009 | US7592331 2-(1-Amino-isoquinolin-6-ylamino)-4,11-diazatricyclo[14.2.2.1(6,10)]henicosa-1(19),6,8,10(21),16(20),17-hexaene-3,12-dione trifluoroacetic acid salt; serine protease inhibitors; arterial cardiovascular thromboembolic disorders; cerebral, kidney, pulmonary embolisms; acute coronary syndrome;prosthetics |
| 09/22/2009 | US7592330 Administering FK-506 following retinal detachment, suppressing endogenous calcineurin, inhibiting cleavage of calcineurin |
| 09/22/2009 | US7592329 containing an anti-inflammatory and anti-allergic compound of the androstane series |
| 09/22/2009 | US7592328 Natural cyclodextrin complexes |
| 09/22/2009 | US7592327 Asthma/allergy therapy that targets T-lymphocytes and/or eosinophils |
| 09/22/2009 | US7592326 Method for stimulating the immune, inflammatory or neuroprotective response |
| 09/22/2009 | US7592325 Methods and compositions for the treatment of eye disorders with increased intraocular pressure |
| 09/22/2009 | US7592324 which include carbonic anhydrase II, IV, and XII, beta 1- and beta 2 adrenergic receptors, acetylcholinesterase, Na+/K+-ATPase, and Na K-2Cl cotransporter; RNA interference; intraocular hypertension, glaucoma |
| 09/22/2009 | US7592323 Testosterone-repressed prostate message-2 (TRPM-2); delaying progression of prostatic tumor cells to an androgen-independent state |
| 09/22/2009 | US7592322 RNAi modulation of RSV, PIV and other respiratory viruses and uses thereof |
| 09/22/2009 | US7592321 Preventing/inhibiting metabolic disorders characterized by absence or reduced levels of alpha-L-iduronidase in newborn mammals by administering recombinant lentivirus comprising nucleic acid segment encoding alpha-L-iduronidase |
| 09/22/2009 | US7592320 Messenger RNA sequence comprising translatable sequence encoding toxin and untranslated sequence which inhibits translation of toxin sequence under conditions existing within mammalian cells that overexpress eukaryotic initiation factor eIF4 |
| 09/22/2009 | US7592318 88kDa tumorigenic growth factor and antagonists |
| 09/22/2009 | US7592317 Promoters operatively linked to genes encoding radiosensitizing or radioprotecting factors, administered to cells, tissues, or patients in conjunction with radiation exposure; tissue-targeted therapy |
| 09/22/2009 | US7592316 Peptides as NS3-serine protease inhibitors of hepatitis C virus |
| 09/22/2009 | US7592305 Use of ghrelin for treating malnutrition in gastrectomized individuals |
| 09/22/2009 | US7592300 Skin cleaning compounds, body splash, surgical scrub, wound care agents, hand sanitizers, disinfectants, mouthwashes, pet shampoos, hard surface sanitizer; reduction of bacteria, rotavirus, or rhinovirus on skin surface; topical |
| 09/22/2009 | US7592177 Compositions and methods for inducing cell dedifferentiation |
| 09/22/2009 | US7592149 Can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 184P1E2 can be used in active or passive immunization |
| 09/22/2009 | US7592143 Induction of capacse cascade ; administering apoptosis inducing protein; drug screening; anticancer agents |
| 09/22/2009 | US7592002 Sugar esters for depilation (hair removal), demabrasion, and wrinkles reduction |
| 09/22/2009 | US7591949 Method for the improvement of transport across adaptable semi-permeable barriers |
| 09/22/2009 | CA2523960C Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors |
| 09/22/2009 | CA2503767C Pyridopyrrolizine and pyridoindolizine derivatives |
| 09/22/2009 | CA2487450C (2s)-2-ethylphenylpropanoic acid derivatives |
| 09/22/2009 | CA2474627C R-(-)-1-[2-(7-chlorobenzo[b]thiophen-3-yl-methoxy)-2-(2,4-dichlorophenyl)-ethyl]-1h-imidazole |
| 09/22/2009 | CA2454584C Pharmaceutical composition for treatment of diseases associated with decrease in bone mass comprising ep4 agonist as active ingredient |
| 09/22/2009 | CA2450833C Compositions comprising thylakoids useful in the modulation of the inflammation process |
| 09/22/2009 | CA2449917C Amino acid mixture-containing agent capable of raising body temperature for food or drink use and medical use |
| 09/22/2009 | CA2432534C Gel composition and trans-scrotal application of a composition for the treatment of hypogonadism |
| 09/22/2009 | CA2419588C Piperidine derivatives for use 2,3-oxidosqualene-lanosterol cyclase inhibitors |
| 09/22/2009 | CA2402121C Method for increasing intestinal absorption of fat soluble vitamins in post-menopausal women and lower animals |
| 09/22/2009 | CA2400236C Use of indoloquinoxaline derivatives for preparing a drug for the treatment of multiple sclerosis |
| 09/22/2009 | CA2399451C Tyrosine derivatives with anti-leukotriene activity |
| 09/22/2009 | CA2398274C Adenosine receptor modulators |
| 09/22/2009 | CA2397554C Combinations comprising dipeptidylpeptidase-iv inhibitors and antidiabetic agents |
| 09/22/2009 | CA2396720C Thiazolyl amide derivatives |
| 09/22/2009 | CA2377128C Composition for the prevention of muscle fatigue and skeletal muscle adaptation to strenuous exercise |
| 09/22/2009 | CA2372664C Substituted benzimidazole, the production thereof and the use thereof as means against parasitic protozoa |
| 09/22/2009 | CA2360894C (1-phenacyl-3-phenyl-3-piperidylethyl) piperidine derivatives, method for the production thereof and pharmaceutical compositions containing the same |
| 09/22/2009 | CA2353727C Use of amtolmetin guacyl for the production of anti-inflammatory drugs for intestinal inflammations |
| 09/22/2009 | CA2353604C Polymeric coatings for controlled delivery of active agents |
| 09/22/2009 | CA2333086C Cocaine receptor binding ligands |
| 09/22/2009 | CA2331854C Nutritional product for a person having renal failure |
| 09/22/2009 | CA2331284C Solution comprising prostaglandins and benzyl alcohol |
| 09/22/2009 | CA2278586C Coated implantable medical device |
| 09/22/2009 | CA2223703C Method of inhibiting viral replication in eukaryotic cells and of inducing apoptosis of virally-infected cells |
| 09/22/2009 | CA2209640C Cycloalkano-pyridines |
| 09/22/2009 | CA2194476C Anti-adhesion agent |
| 09/22/2009 | CA2152351C Combination of a cholesterol biosynthesis inhibitor and a .beta.-lactam cholesterol absorption inhibitor |
| 09/19/2009 | CA2717166A1 Methods of modulating t cell-dependent immune responses |
| 09/17/2009 | WO2009114874A2 Benzothiazole kinase inhibitors and methods of use |
| 09/17/2009 | WO2009114870A2 Kinase inhibitors and methods of use |
| 09/17/2009 | WO2009114856A2 Aurora kinase inhibitors |
| 09/17/2009 | WO2009114826A2 Treatment systems and methods for renal-related diseases |
| 09/17/2009 | WO2009114810A2 Use of ellagitannins as inhibitors of bacterial quorum sensing |
| 09/17/2009 | WO2009114809A1 Therapies for cancer using isotopically substituted lysine |
| 09/17/2009 | WO2009114773A2 Modified release formulations of anti-irritability drugs |
| 09/17/2009 | WO2009114749A2 Carrageenan modified by ion-exchange process |
| 09/17/2009 | WO2009114745A1 Formulations of vitamin k analogs for topical use |
| 09/17/2009 | WO2009114744A1 Therapeutic compounds |
| 09/17/2009 | WO2009114740A2 USE OF GABAa RECEPTOR ANTAGONISTS FOR THE TREATMENT OF EXCESSIVE SLEEPINESS AND DISORDERS ASSOCIATED WITH EXCESSIVE SLEEPINESS |
| 09/17/2009 | WO2009114729A2 Compounds, compositions and methods for treating lysosomal storage diseases and disorders |
| 09/17/2009 | WO2009114726A1 Compositions comprising notch1 sirna and methods of use thereof |
| 09/17/2009 | WO2009114725A2 Mobilization of hematopoietic stem cells |
| 09/17/2009 | WO2009114724A2 COMPOSITIONS COMPRISING NUCLEAR FACTOR-KAPPA B (NF-ĸB) SIRNA AND METHODS OF USE |
| 09/17/2009 | WO2009114718A2 Methods and assays for detecting and treating hypoglycemia |